Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management
Saved in:
| Published in: | Thoracic Cancer |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868553993430499328 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Thoracic Cancer |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:93185 |
| institution | FRELIP |
| journal_source_facet | Thoracic Cancer |
| last_indexed | 2026-06-20T21:45:41.950Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_alt | Asociación entre reducción de dosis de osimertinib y resultados del tratamiento en NSCLC avanzado con mutación EGFR en primera línea: el impacto del manejo post-progresión Association entre la réduction de dose d'osimertinib et les résultats du traitement dans le NSCLC avancé muté EGFR en première ligne : l'impact de la gestion post-progression Associação entre Redução da Dose de Osimertinibe e Desfechos do Tratamento em NSCLC Avançado com Mutação de EGFR em Primeira Linha: O Impacto do Manejo Pós-Progressão |
| title_auth | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_es_txt | Asociación entre reducción de dosis de osimertinib y resultados del tratamiento en NSCLC avanzado con mutación EGFR en primera línea: el impacto del manejo post-progresión |
| title_fr_txt | Association entre la réduction de dose d'osimertinib et les résultats du traitement dans le NSCLC avancé muté EGFR en première ligne : l'impact de la gestion post-progression |
| title_full | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_fullStr | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_full_unstemmed | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_pt_txt | Associação entre Redução da Dose de Osimertinibe e Desfechos do Tratamento em NSCLC Avançado com Mutação de EGFR em Primeira Linha: O Impacto do Manejo Pós-Progressão |
| title_short | Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management |
| title_sort | association between osimertinib dose reduction and treatment outcomes in first‐line egfr‐mutated advanced nsclc: the impact of post‐progression management |
| topic | Oncology General Oncology |
| url | https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.70328?af=R |